EMS and BD Launch Semaglutide Therapy in Brazil, Expanding GLP-1 Access with Advanced Injection Pen Platform
核心洞察
EMS (搜索) and BD have partnered to launch a semaglutide therapy in Brazil targeting obesity (搜索) and type 2 diabetes (搜索), announced on July 29, 2026.
The therapy utilizes BD's Vystra™ Injection Pen platform, designed for intuitive self-injection to improve patient adherence and ease of use.
The collaboration aims to address rising global demand for GLP-1 (搜索) therapies by pairing scalable, patient-centric delivery technology with EMS (搜索)'s pharmaceutical leadership.
BD (Becton, Dickinson and Company) (搜索) and EMS (搜索), one of Brazil's leading pharmaceutical companies, announced on July 29, 2026, their collaboration to launch a semaglutide therapy in Brazil. The partnership pairs EMS's pharmaceutical expertise with BD's advanced drug delivery technology to address the growing burden of chronic metabolic diseases, including obesity (搜索) and type 2 diabetes (搜索), in the Brazilian market.
The launch comes amid surging global demand for GLP-1 (搜索) receptor agonist therapies, which has underscored the critical need for delivery systems that enable safe, accurate, and consistent dosing. Many patients face challenges with ease of use, confidence with self-injection, and adherence to treatment, making intuitive and reliable delivery solutions increasingly important.
BD Vystra™ Injection Pen Platform at the Core
EMS (搜索)'s semaglutide will be administered using BD's established injection pen platform, the BD Vystra™ Injection Pen. The platform features an intuitive design built specifically for ease of use, reflecting BD's deep expertise in drug delivery systems design and manufacturing. The technology supports scalable solutions that can help meet the rising demand for injectable therapies.
"BD's partnership with EMS (搜索) introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research-backed design that supports usability for self-injection."
Expanding Access to Metabolic Therapies in Brazil
The collaboration represents a significant step in broadening access to advanced metabolic therapies in Latin America's largest pharmaceutical market. EMS (搜索), with more than 60 years of experience developing and delivering therapies, operates across prescription medicines, generics, and over-the-counter products, with a growing global footprint spanning more than 60 countries.
"Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS (搜索). "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike."
EMS (搜索) continues to invest in advanced manufacturing and research and development, including peptide capabilities to support GLP-1 (搜索) therapies for obesity (搜索) and type 2 diabetes (搜索). The company's investment in peptide manufacturing infrastructure positions it to meet growing domestic and international demand for these therapies.
Addressing Unmet Needs in Chronic Disease Management
The partnership underscores a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases. By combining a proven therapeutic agent with a delivery system designed for patient usability, the collaboration aims to improve treatment adherence and clinical outcomes for individuals managing obesity (搜索) and type 2 diabetes (搜索) in Brazil.